Infectious diseases place a significant impact on the healthcare system. It causes 7.7 million fatalities each year, with a disproportionately high burden in sub-Saharan Africa. Drug resistant pathogens attributed to 4.95 million and 1.27 million are illnesses of bacteria that are resistant to the current medications. Therefore, there is an urgent need for new, safe, and effective compounds to combat antimicrobial resistance. The aim of this study was to synthesize new compounds derived from 2-hydroxy-1, 2-diphenylethanone using the Mannich reaction and evaluate their antimicrobial activities against 26 bacterial strains and 4 fungal strains. Three compounds were successfully synthesized and their structures were confirmed as 3 (diethylamino)-2-hydroxy-1, 2-diphenylpropan-1-one (2) 1-(2-hydroxy-3-oxo-2, 3 diphenylpropyl) urea (3), and 2-hydroxy-1, 2-diphenyl-3-(piperidin-1-yl) propan-1-one (4), using 1H and 13C-NMR spectroscopy. All the synthesized compounds exhibited broad-spectrum antibacterial activity. Compound (3) demonstrated the highest activity, with MIC of 10 µg/mL against Shigella sonnei 1, Shigella boydii D13629, and Pseudomonas aeruginosa MDR1 and compound (4) demonstrated the highest antifungal activity, with MIC of 200 µg/mL against Candida albicans ATCC 10231, Aspergillus niger ATCC 6275, Penicillium funiculosum NCTC 287, and Penicillium notatum ATCC 11625. Molecular docking showed the compounds interact favorably with conserved residues in the binding site of E. coli DsbA (PDB ID: 8DN0) through hydrogen bonding and hydrophobic interactions, with docking scores of –7.5 kcal/mol compound (3), –7.1 kcal/mol compound (4), and –6.5kcal/mol compound (2). This research suggests verify the molecular docking results experimentally and biological activities, such as antiviral, anticancer, anti-inflammatory, and antioxidant properties and evaluate the safety profile of the produced chemicals.
| Published in | World Journal of Health Services Research (Volume 1, Issue 1) |
| DOI | 10.11648/j.wjhsr.20260101.11 |
| Page(s) | 1-13 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
2-hydroxy-1, 2-diphenylethanone, Antimicrobial Activity, In-silico Studies, Disulfide Bond Oxidoreductase, Mannich Reaction
Compound | MF | MW | Color | PS | Yield | Rf value |
|---|---|---|---|---|---|---|
2 | C19H23NO2 | 297.37 | White | Crystal | 56% | 0.7 |
3 | C17H17NO3 | 284.31 | White | Crystal | 24% | 0.4 |
4 | C20H23NO2 | 309.40 | Yellowish | Powder | 64% | 0.8 |
Bacteria strain | ZOI in mm (200µg/ml) | MIC (µg/ml) | |||||
|---|---|---|---|---|---|---|---|
2 | 3 | 4 | Ciprofloxacin | 2 | 3 | 4 | |
E.coli K99 | 13.5±0.5 | 12.2±0.6 | 13.5±0.5 | 16.0±1.0 | 25 | 100 | 25 |
E.coli K88 | 14.8 ± 0.8 | 12.5±0.0 | 14.8±0.8 | 17.0 ±0.0 | 25 | 100 | 25 |
E.coli 306 | 14.0 ± 0.9 | 13.0±0.5 | 14.3±0.6 | 17.0 ± 1.0 | 25 | 100 | 25 |
E.coli LT37 | 14.0 ± 0.0 | 12.5±0.0 | 14.0±0.0 | 16.0 ± 0.0 | 25 | 100 | 25 |
E.coli 872 | 14.5 ± 0.5 | 12.7±0.3 | 14.5±0.5 | 15.8± 0.8 | 25 | 100 | 25 |
E.coli ROW 7/12 | 15.0±0.0 | 12.0±1.0 | 14.5±0.5 | 16.5 ±0.0 | 25 | 100 | 25 |
E.coli 3: 37C | 15.2 ±0.3 | 11.5±0.5 | 15.2±0.3 | 16.5 ± 1.0 | 25 | 100 | 25 |
E.coli CD/99/1 | 15.7±0.3 | 12.3±0.3 | 15.7±0.3 | 16.8±0.8 | 25 | 100 | 25 |
Salmonella typhi Ty2 | 13.2±0.3 | 13.7±1.0 | 11.8±0.8 | 16.0±0.0 | 400 | 100 | 800 |
Salmonella enterica TD 01 | 14.2±0.3 | 14.0±1.0 | 12.7±0.8 | 19.0±0.5 | 400 | 100 | 800 |
Shigella dysentery 8 | 13.8±0.8 | 13.7±0.6 | 13.8±0.8 | 20.0±0.0 | 100 | 100 | 100 |
Shigella soneii 1 | 14.0±0.0 | 15.8±0.8 | 14.0±0.0 | 19.5±0.0 | 50 | 10 | 50 |
Shigella boydii D13629 | 14.0±1.0 | 15.8±0.3 | 14.0±1.0 | 20.0±0.0 | 50 | 10 | 50 |
Shigella Flexineri Type 6 | 15.8±0.3 | 15.5±1.0 | 15.8±0.3 | 20.5±0.0 | 50 | 50 | 50 |
Staphylococcus aureus MDR10 | 14.3±0.6 | 14.7±0.8 | 14.3±0.6 | 18.0±0.0 | 100 | 400 | 100 |
Bacillus pumilus 82 | 9.0±0.0 | 6.0±0.0 | 8.0±0.0 | 18.8±0.8 | 200 | 400 | 800 |
Bacillus subtilis ATCC 6633 | 10.2±0.8 | 6.0±0.0 | 7.5±0.0 | 18.0±0.5 | 200 | 400 | 800 |
Vibrio cholerae 1313 | 12.0±0.0 | 13.3±0.3 | 12.0±0.0 | 17.5±0.0 | 100 | 25 | 100 |
Vibrio cholerae 293 | 12.3±0.3 | 14.7±0.6 | 12.3±0.3 | 18.7±0.8 | 100 | 25 | 100 |
Vibrio cholerae 1315 | 11.3±1.3 | 14.8±0.6 | 11.3±1.3 | 19.0±0.5 | 100 | 25 | 100 |
Vibrio cholerae 85 | 11.2±0.5 | 14.0±0.0 | 11.5±0.5 | 18.5±0.5 | 100 | 25 | 100 |
E.coli HB101* | 13.2±0.3 | 14.0±0.0 | 12.2±0.3 | 16.0±0.0 | 200 | 25 | 100 |
E.coli C600* | 13.0±0.0 | 13.8±0.3 | 12.8±0.3 | 16.0±0.0 | 200 | 25 | 100 |
S.aureus MDR 1* | 14.2±0.3 | 14.2±0.3 | 14.3±0.6 | 18.0±0.6 | 100 | 25 | 100 |
S.aureus MDR 2* | 14.3±0.6 | 14.7±0.8 | 14.3±0.6 | 18.0±0.0 | 100 | 25 | 100 |
Pseudomonas aeruginosa MDR 1* | 14.0±0.3 | 14.8±0.3 | 13.0±0.0 | 17.3±0.3 | 200 | 10 | 50 |
Fungi | ZOI (2000 µg/ml) MIC (µg/ml) | MIC (µg/ml) | |||||
|---|---|---|---|---|---|---|---|
2 | 3 | 4 | Griseofulvin | 2 | 3 | 4 | |
Candida albicans ATCC 10231 | 12.0 ±0.2 | 12.5 ±0.3 | 15.0 ± 0.2 | 16.0 ±0.2 | 1000 | 1000 | 200 |
Aspergillus Niger ATCC 6275 | 13.0 ± 0.1 | 14.0 ±0.1 | 15.0 ±0.1 | 15.0 ±0.2 | 400 | 800 | 200 |
Penicillium notatum ATCC 11625 | 13.5 ± 0.3 | 14.5 ±0.2 | 15.0± 0.0 | 15.0 ±0.1 | 800 | 800 | 200 |
Penicillium funiculosum NCTC 287 | 13.0 ±0.3 | 12.5 ± 0.3 | 15.0 ±0.2 | 14.0 ± 0.4 | 800 | 800 | 200 |
Compound | Caco-2 (Log unite) | Pgp-inhib | HIA | PPB (%) | VD (L/Kg) | BBB-Penet | CYP450 inhibition | Excretion | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1A2 | 2C19 | 2C9 | 2D6 | 3A4 | CL | t1/2 (hr) | |||||||
2 | -4.581 | 0.027 | 0.006 | 74.92 | 2.496 | 0.850 | 0.624 | 0.906 | 0.025 | 0.941 | 0.697 | 7.82 | 0.08 |
3 | -5.219 | 0.042 | 0.202 | 71.23 | 0.734 | 0.996 | 0.636 | 0.539 | 0.145 | 0.215 | 0.310 | 2.088 | 0.194 |
4 | -4.692 | 0.896 | 0.015 | 81.14 | 3.695 | 0.875 | 0.274 | 0.142 | 0.038 | 0.636 | 0.086 | 3.556 | 0.043 |
Optimal Value | >-5.00 | 0-0.3 | 0-0.3 | <90% | 0.04-20 | 0-0.3 | 0-1 | 0-1 | 0-1 | 0-1 | 0-1 | >=5 | 0-0.3 |
Compound | NHA | nHD | Not | PSA | Logs | LogP | Lord | SC | her | AMES | H-HT | Carcinogen |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 3 | 1 | 7 | 40.54 | -3.934 | 3.173 | 3.214 | 1 | 0.351 | 0.049 | 0.051 | 0.019 |
3 | 5 | 4 | 6 | 92.42 | -3.133 | 1.599 | 1.95 | 1 | 0.12 | 0.151 | 0.079 | 0.018 |
4 | 3 | 1 | 5 | 40.54 | -4.199 | 3.401 | 3.39 | 1 | 0.62 | 0.053 | 0.064 | 0.034 |
Optimal Value | 0-12 | 0-7 | 0-11 | 0-140 | -4 to 0.5 log mol/L | 0 to 3 log mol/L | 1 to 3 log mol/L | <=2 | 0-0.3 | 0-0.3 | 0-0.3 | 0-0.3 |
Compound | QED | Fsp3 | Score | LR-5 | Golden Triangle | PAINS |
|---|---|---|---|---|---|---|
2 | 0.798 | 0.316 | 2.593 | Accepted | Accepted | 0 alerts |
3 | 0.725 | 0.125 | 2.65 | Accepted | Accepted | 0 alerts |
4 | 0.862 | 0.35 | 2.55 | Accepted | Accepted | 0 alerts |
Optimal Value | ≥ 0.67 | ≥ 0.42 | ≤ 6 | < 2 violations | 0 - violations | 0 |
Compound | Cavity size (Angstrom cubed (Å3) | Docking score (kcal/mol) | Interaction with amino acid residues | |
|---|---|---|---|---|
H-bonds | Hydrophobic | |||
Native ligand | 926 | -6.7 | HIS32, | PHE36 |
2 | 926 | -6.5 | HIS32, | PHE36 |
3 | 926 | -7.5 | HIS32, PHE36, THR161, PRO163 | PHE174, LEU40, |
4 | 926 | -7.1 | HIS32, THR168 | PHE174 |
ADMET | Absorption, Distribution, Metabolism, Excretion and Toxicity |
AMR | Anti-Microbial Resistance |
DMSO | Dimethyl Sulfoxide |
MIC | Minim Inhibitatory Concentration |
PDB | Protein Data Bank |
TLC | Thin Layer Chromatography |
UV | Ultra Violet |
ZOI | Zone of Inhibition |
| [1] | R. L. Berkelman, R. T. Bryan, M. T. Osterholm, J. W. LeDuc, and J. M. Hughes, “Infectious Disease Surveillance: a Crumbling Foundation,” Science (80-.)., vol. 264, no. 5157, pp. 368–370, Apr. 1994. |
| [2] | A. Rathore, S. Sharma, and M. Sharma, “Challenges in Infectious Disease Management,” in Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases, John Wiley & Sons, Ltd, 2025, pp. 51–79. |
| [3] | I. N. Okeke et al., “The scope of the antimicrobial resistance challenge,” Lancet, vol. 403, no. 10442, 2024, pp. 2426–2438. |
| [4] | J. M. Pieniążek et al., “Overview Of The Main Bacterial Infections In Humans,” Qual. Sport, vol. 23, p. 54786, Sep. 2024. |
| [5] | S. K. Sarsamkar and N. S. Gramopadhye, “Characterization and Antimicrobial Activity of New Cobalt-Nickel-Copper (Ii) Complexes with Benzoin and 3-Amino Benzoic Acid,” SSRN Electron. J., no. Ii, 2021. |
| [6] | N. Yaylı et al., “Molecular docking, synthesis and biological evaluation (enzyme inhibition, antimicrobial and antioxidant) of methoxy benzoin/benzil/stilbenoid derivatives,” Org. Commun., vol. 15, no. 2, pp. 129–147, 2022. |
| [7] | C. G. Fernández, “Benzoin, a resin produced by Styrax trees in North Sumatra Province, Indonesia,” For. Prod. livelihoods Conserv. case Stud. non-timber For. Prod. Syst., vol. 1, p. 148, 2004. |
| [8] | H. N. Atia Sharif, R. Rehman, A. Mushtaq, and U. A. Rashid, “Review on bioactive potential of Benzoin resin,” Int. J. Chem. Biochem. Sci, vol. 10, pp. 106–110, 2016. |
| [9] | K. Buran, “Metal complexes of sulfamethazine/benzoin-based Schiff base ligand: synthesis, characterization, DFT calculations, and antimicrobial activities,” Turkish J. Biol., vol. 49, no. SI-1, pp. 118–126, 2025. |
| [10] | R. Babu Kothapalli, B. Anusha, M. Naveen Kumar, P. S. Singh, S. Ramakrishna, and U. Venkata Subba Reddy, “Deracemization of Benzoin and its Derivatives via Kinetic, Dynamic Kinetic, Aerobic Oxidative Kinetic, and Reagent‐mediated resolution,” Chem. Asian J., p. e202401693, 2025. |
| [11] | K. Keenan, J. Silva Corrêa, L. Sringernyuang, S. Nayiga, and C. I. R. Chandler, “The social burden of antimicrobial resistance: what is it, how can we measure it, and why does it matter?,” JAC-Antimicrobial Resist., vol. 7, no. 2, pp. 1–10, 2025. |
| [12] | WHO, WHO bacterial priority pathogens list, 2024. |
| [13] | R. Nassar, G. L. Dignon, R. M. Razban, and K. A. Dill, “The Protein Folding Problem: The Role of Theory,” Journal of Molecular Biology, vol. 433, no. 20. Academic Press, p. 167126, Oct. 01, 2021. |
| [14] | C. Santos-Martin et al., “Structural bioinformatic analysis of DsbA proteins and their pathogenicity associated substrates,” Computational and Structural Biotechnology Journal, vol. 19. Elsevier, pp. 4725–4737, Jan. 01, 2021. |
| [15] | M. S. Iorungwa and R. A. Wuana, “Original Research article Synthesis, Characterization, Kinetics, Thermodynamic and Antimicrobial Studies of Fe (III), Cu (II), Zn (II), N, N ’ -Bis (2- hydroxy-1, 2-diphenylethanone) ethylenediamine Complexes,” no. May, 2019. |
| [16] | F. F. Blicke, “The Mannich Reaction,” Org. React., vol. 1, pp. 303–341, 1942. |
| [17] | J. H. Jorgensen and J. D. Turnidge, “Susceptibility test methods: dilution and disk diffusion methods,” Man. Clin. Microbiol., pp. 1253–1273, 2015. |
| [18] | O. Daliri Shamsabadi, “Investigation of Antimicrobial Effect and Mechanical Properties of Modified Starch Films, Cellulose Nanofibers, and Citrus Essential Oils by Disk Diffusion Method,” Asian J. Green Chem., vol. 8, no. 1, pp. 1–14, 2024. |
| [19] | R. M. Humphries et al., “CLSI methods development and standardization working group best practices for evaluation of antimicrobial susceptibility tests,” J. Clin. Microbiol., vol. 56, no. 4, pp. 10–1128, 2018. |
| [20] | C. D. Steward et al., “Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β-lactamase detection methods,” J. Clin. Microbiol., vol. 39, no. 8, pp. 2864–2872, 2001. |
| [21] | I. Wiegand, K. Hilpert, and R. E. W. Hancock, “Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances,” Nat. Protoc., vol. 3, no. 2, pp. 163–175, 2008. |
| [22] | O. Trott and A. J. Olson, “AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” J. Comput. Chem., vol. 31, no. 2, pp. 455–461, Jan. 2010. |
| [23] | J. Dong et al., “ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database,” J. Cheminform., vol. 10, pp. 1–11, 2018. |
| [24] | A. Garrido, A. Lepailleur, S. M. Mignani, P. Dallemagne, and C. Rochais, “hERG toxicity assessment: Useful guidelines for drug design,” Eur. J. Med. Chem., vol. 195, p. 112290, 2020. |
| [25] | W. G.. H. B., “E.coli DsbA in complex with N-(2-fluorophenyl)-5-methylisoxazole-3-carboxamide,” Jun. 2023. |
APA Style
Kusse, T., Bisrat, D., Asres, K., Mazumder, A. (2026). Synthesis, In vitro Antimicrobial, and In Silico Studies of 2-Hydroxy-1, 2-Diphenylethanone Derivatives. World Journal of Health Services Research, 1(1), 1-13. https://doi.org/10.11648/j.wjhsr.20260101.11
ACS Style
Kusse, T.; Bisrat, D.; Asres, K.; Mazumder, A. Synthesis, In vitro Antimicrobial, and In Silico Studies of 2-Hydroxy-1, 2-Diphenylethanone Derivatives. World J. Health Serv. Res. 2026, 1(1), 1-13. doi: 10.11648/j.wjhsr.20260101.11
@article{10.11648/j.wjhsr.20260101.11,
author = {Temesgen Kusse and Daniel Bisrat and Kaleab Asres and Avijit Mazumder},
title = {Synthesis, In vitro Antimicrobial, and In Silico Studies of
2-Hydroxy-1, 2-Diphenylethanone Derivatives},
journal = {World Journal of Health Services Research},
volume = {1},
number = {1},
pages = {1-13},
doi = {10.11648/j.wjhsr.20260101.11},
url = {https://doi.org/10.11648/j.wjhsr.20260101.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjhsr.20260101.11},
abstract = {Infectious diseases place a significant impact on the healthcare system. It causes 7.7 million fatalities each year, with a disproportionately high burden in sub-Saharan Africa. Drug resistant pathogens attributed to 4.95 million and 1.27 million are illnesses of bacteria that are resistant to the current medications. Therefore, there is an urgent need for new, safe, and effective compounds to combat antimicrobial resistance. The aim of this study was to synthesize new compounds derived from 2-hydroxy-1, 2-diphenylethanone using the Mannich reaction and evaluate their antimicrobial activities against 26 bacterial strains and 4 fungal strains. Three compounds were successfully synthesized and their structures were confirmed as 3 (diethylamino)-2-hydroxy-1, 2-diphenylpropan-1-one (2) 1-(2-hydroxy-3-oxo-2, 3 diphenylpropyl) urea (3), and 2-hydroxy-1, 2-diphenyl-3-(piperidin-1-yl) propan-1-one (4), using 1H and 13C-NMR spectroscopy. All the synthesized compounds exhibited broad-spectrum antibacterial activity. Compound (3) demonstrated the highest activity, with MIC of 10 µg/mL against Shigella sonnei 1, Shigella boydii D13629, and Pseudomonas aeruginosa MDR1 and compound (4) demonstrated the highest antifungal activity, with MIC of 200 µg/mL against Candida albicans ATCC 10231, Aspergillus niger ATCC 6275, Penicillium funiculosum NCTC 287, and Penicillium notatum ATCC 11625. Molecular docking showed the compounds interact favorably with conserved residues in the binding site of E. coli DsbA (PDB ID: 8DN0) through hydrogen bonding and hydrophobic interactions, with docking scores of –7.5 kcal/mol compound (3), –7.1 kcal/mol compound (4), and –6.5kcal/mol compound (2). This research suggests verify the molecular docking results experimentally and biological activities, such as antiviral, anticancer, anti-inflammatory, and antioxidant properties and evaluate the safety profile of the produced chemicals.},
year = {2026}
}
TY - JOUR T1 - Synthesis, In vitro Antimicrobial, and In Silico Studies of 2-Hydroxy-1, 2-Diphenylethanone Derivatives AU - Temesgen Kusse AU - Daniel Bisrat AU - Kaleab Asres AU - Avijit Mazumder Y1 - 2026/09/09 PY - 2026 N1 - https://doi.org/10.11648/j.wjhsr.20260101.11 DO - 10.11648/j.wjhsr.20260101.11 T2 - World Journal of Health Services Research JF - World Journal of Health Services Research JO - World Journal of Health Services Research SP - 1 EP - 13 PB - Science Publishing Group UR - https://doi.org/10.11648/j.wjhsr.20260101.11 AB - Infectious diseases place a significant impact on the healthcare system. It causes 7.7 million fatalities each year, with a disproportionately high burden in sub-Saharan Africa. Drug resistant pathogens attributed to 4.95 million and 1.27 million are illnesses of bacteria that are resistant to the current medications. Therefore, there is an urgent need for new, safe, and effective compounds to combat antimicrobial resistance. The aim of this study was to synthesize new compounds derived from 2-hydroxy-1, 2-diphenylethanone using the Mannich reaction and evaluate their antimicrobial activities against 26 bacterial strains and 4 fungal strains. Three compounds were successfully synthesized and their structures were confirmed as 3 (diethylamino)-2-hydroxy-1, 2-diphenylpropan-1-one (2) 1-(2-hydroxy-3-oxo-2, 3 diphenylpropyl) urea (3), and 2-hydroxy-1, 2-diphenyl-3-(piperidin-1-yl) propan-1-one (4), using 1H and 13C-NMR spectroscopy. All the synthesized compounds exhibited broad-spectrum antibacterial activity. Compound (3) demonstrated the highest activity, with MIC of 10 µg/mL against Shigella sonnei 1, Shigella boydii D13629, and Pseudomonas aeruginosa MDR1 and compound (4) demonstrated the highest antifungal activity, with MIC of 200 µg/mL against Candida albicans ATCC 10231, Aspergillus niger ATCC 6275, Penicillium funiculosum NCTC 287, and Penicillium notatum ATCC 11625. Molecular docking showed the compounds interact favorably with conserved residues in the binding site of E. coli DsbA (PDB ID: 8DN0) through hydrogen bonding and hydrophobic interactions, with docking scores of –7.5 kcal/mol compound (3), –7.1 kcal/mol compound (4), and –6.5kcal/mol compound (2). This research suggests verify the molecular docking results experimentally and biological activities, such as antiviral, anticancer, anti-inflammatory, and antioxidant properties and evaluate the safety profile of the produced chemicals. VL - 1 IS - 1 ER -